ERIC 2018 | A perspective on MRD in CLL: treatment efficacy, early relapse detection & more
Eva Kimby
• 25 Oct 2018
Measurable residual disease (MRD) measurement has the potential to inform us about the efficacy of chronic lymphocytic leukemia (CLL) treatments on an extremely sensitive level, in addition to signaling early relapse and many other uses. Speaking from the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain, Eva Kimby, MD, PhD, of the Karolinska University Hospital, Solna, Sweden, gives us her insights into the use of MRD in the field of CLL.
